Literature DB >> 19412669

Role of physiological intestinal water in oral absorption.

Steven C Sutton1.   

Abstract

Water volume has impact when the compound has low aqueous solubility. For example, the absorption of compounds with a Biopharmaceutics Classification System class 2 or 4 is likely to be solubility-limited. Provided the formulation does not contribute to a dissolution-limited condition (e.g., particle size, Waterman and Sutton, J Control Release 86:293-304, 2003) and permeability is rapid, any impact on solubility factors in the gastrointestinal (GI) tract will directly impact the fraction absorbed These factors are in situ solubility, precipitation, and volume of water. Using GastroPlus, models were developed with literature values of water volume in the small (SIWV) and large (LIWV) intestines for several solubility limited compounds. One or more models were developed for the mean plasma concentration-time profile of each compound. The consistency of the models with known literature and experimental data for the compounds' solubility and precipitation was determined. The SIWV associated with best fits of solubility limited compounds averaged about 130 ml, with a range of 10-150 ml in the fasted state. The average LIWV in the fasted state was about 10 ml and ranged as large as 125 ml. The wide range of individual LIWV values is likely due to variability in pharmacokinetics, permeability, GI transit, and the observation that data set was collected during a "snapshot in time". The preferred values of 10% organ volume for small intestine and 1-10% organ volume for large intestine are recommended in lieu of the GastroPlus default values of 40% and 10%, respectively.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19412669      PMCID: PMC2691455          DOI: 10.1208/s12248-009-9087-2

Source DB:  PubMed          Journal:  AAPS J        ISSN: 1550-7416            Impact factor:   4.009


  23 in total

1.  Formulation-dependent food effects demonstrated for nifedipine modified-release preparations marketed in the European Union.

Authors:  Barbara S Schug; Erich Brendel; Dörte Wolf; Meinolf Wonnemann; Manfred Wargenau; Henning H Blume
Journal:  Eur J Pharm Sci       Date:  2002-04       Impact factor: 4.384

Review 2.  Solubility: it's not just for physical chemists.

Authors:  Shobha N Bhattachar; Laura A Deschenes; James A Wesley
Journal:  Drug Discov Today       Date:  2006-09-26       Impact factor: 7.851

Review 3.  Water and electrolyte movement in the intestine.

Authors:  J S Fordtran; J M Dietschy
Journal:  Gastroenterology       Date:  1966-02       Impact factor: 22.682

4.  In silico modeling of non-linear drug absorption for the P-gp substrate talinolol and of consequences for the resulting pharmacodynamic effect.

Authors:  Marija Tubic; Daniel Wagner; Hilde Spahn-Langguth; Michael B Bolger; Peter Langguth
Journal:  Pharm Res       Date:  2006-08       Impact factor: 4.200

5.  A statistical method for the determination of absorption rate constant estimated using the rat single pass intestinal perfusion model and multiple linear regression.

Authors:  Steven C Sutton; M T S Rinaldi; J M McCarthy; K E Vukovinsky
Journal:  J Pharm Sci       Date:  2002-04       Impact factor: 3.534

6.  Estimation of the increase in solubility of drugs as a function of bile salt concentration.

Authors:  S D Mithani; V Bakatselou; C N TenHoor; J B Dressman
Journal:  Pharm Res       Date:  1996-01       Impact factor: 4.200

7.  The disposition of fluoxetine but not sertraline is altered in poor metabolizers of debrisoquin.

Authors:  B A Hamelin; J Turgeon; F Vallée; P M Bélanger; F Paquet; M LeBel
Journal:  Clin Pharmacol Ther       Date:  1996-11       Impact factor: 6.875

8.  Clinical pharmacokinetics of nifedipine gastrointestinal therapeutic system. A controlled-release formulation of nifedipine.

Authors:  M Chung; D P Reitberg; M Gaffney; W Singleton
Journal:  Am J Med       Date:  1987-12-21       Impact factor: 4.965

Review 9.  Salt formation to improve drug solubility.

Authors:  Abu T M Serajuddin
Journal:  Adv Drug Deliv Rev       Date:  2007-05-29       Impact factor: 15.470

10.  Sertraline is metabolized by multiple cytochrome P450 enzymes, monoamine oxidases, and glucuronyl transferases in human: an in vitro study.

Authors:  R Scott Obach; Loretta M Cox; Larry M Tremaine
Journal:  Drug Metab Dispos       Date:  2004-11-16       Impact factor: 3.922

View more
  16 in total

1.  Application of Absorption Modeling in Rational Design of Drug Product Under Quality-by-Design Paradigm.

Authors:  Filippos Kesisoglou; Amitava Mitra
Journal:  AAPS J       Date:  2015-05-22       Impact factor: 4.009

2.  Mathematical Models to Explore Potential Effects of Supersaturation and Precipitation on Oral Bioavailability of Poorly Soluble Drugs.

Authors:  Mary S Kleppe; Kelly M Forney-Stevens; Roy J Haskell; Robin H Bogner
Journal:  AAPS J       Date:  2015-04-08       Impact factor: 4.009

3.  Measurement of drug concentration in the stomach after intragastric administration of drug solution to healthy volunteers: analysis of intragastric fluid dynamics and drug absorption.

Authors:  Shinji Yamashita; Makoto Kataoka; Haruki Higashino; Shinji Sakuma; Takashi Sakamoto; Hinako Uchimaru; Hiroshi Tsukikawa; Masanari Shiramoto; Hitoshi Uchiyama; Hidehisa Tachiki; Shin Irie
Journal:  Pharm Res       Date:  2012-11-21       Impact factor: 4.200

4.  The impact of gastric pH, volume, and emptying on the food effect of ziprasidone oral absorption.

Authors:  Steven C Sutton; Richard Nause; Kuan Gandelman
Journal:  AAPS J       Date:  2017-03-20       Impact factor: 4.009

Review 5.  Physiological parameters for oral delivery and in vitro testing.

Authors:  Deanna M Mudie; Gordon L Amidon; Gregory E Amidon
Journal:  Mol Pharm       Date:  2010-09-07       Impact factor: 4.939

Review 6.  Physiologically Based Pharmacokinetic Modelling for First-In-Human Predictions: An Updated Model Building Strategy Illustrated with Challenging Industry Case Studies.

Authors:  Neil A Miller; Micaela B Reddy; Aki T Heikkinen; Viera Lukacova; Neil Parrott
Journal:  Clin Pharmacokinet       Date:  2019-06       Impact factor: 6.447

7.  Colloid formation by drugs in simulated intestinal fluid.

Authors:  Allison K Doak; Holger Wille; Stanley B Prusiner; Brian K Shoichet
Journal:  J Med Chem       Date:  2010-05-27       Impact factor: 7.446

8.  Physiologically based pharmacokinetic modelling to predict single- and multiple-dose human pharmacokinetics of bitopertin.

Authors:  Neil Parrott; Dominik Hainzl; Daniela Alberati; Carsten Hofmann; Richard Robson; Bruno Boutouyrie; Meret Martin-Facklam
Journal:  Clin Pharmacokinet       Date:  2013-08       Impact factor: 6.447

9.  Translating Human Effective Jejunal Intestinal Permeability to Surface-Dependent Intrinsic Permeability: a Pragmatic Method for a More Mechanistic Prediction of Regional Oral Drug Absorption.

Authors:  Andrés Olivares-Morales; Hans Lennernäs; Leon Aarons; Amin Rostami-Hodjegan
Journal:  AAPS J       Date:  2015-05-19       Impact factor: 4.009

10.  Development of a Prototype, Once-Daily, Modified-Release Formulation for the Short Half-Life RIPK1 Inhibitor GSK2982772.

Authors:  Debra J Tompson; Mark Whitaker; Rennan Pan; Geoffrey Johnson; Teresa Fuller; Litza McKenzie; Vanessa Zann; Marcy Powell; Kathy Abbott-Banner; Simon Hawkins
Journal:  Pharm Res       Date:  2021-06-16       Impact factor: 4.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.